J.L. Bainbridge & Co’s Bristol-Myers Squibb BMY Stock Holding History

J.L. Bainbridge & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-303,693	Closed	-$21.9M	–	77
2022 Q4	$21.9M	Sell	303,693 -551	-0.2%	-$41.5K	3.39%	14
2022 Q3	$21.6M	Sell	304,244 -5,682	-2%	-$412K	3.31%	12
2022 Q2	$23.9M	Sell	309,926 -274,594	-47%	-$20.9M	3.55%	11
2022 Q1	$42.7M	Sell	584,520 -11,224	-2%	-$754K	4.86%	6
2021 Q4	$37.1M	Sell	595,744 -19,443	-3%	-$1.14M	4.13%	7
2021 Q3	$36.4M	Sell	615,187 -13,879	-2%	-$914K	4.34%	6
2021 Q2	$42M	Buy	629,066 +4,779	+0.8%	+$312K	5.02%	4
2021 Q1	$39.4M	Buy	624,287 +4,127	+0.7%	+$257K	5.2%	5
2020 Q4	$38.5M	Sell	620,160 -11,775	-2%	-$724K	5.42%	4
2020 Q3	$38.1M	Sell	631,935 -11,450	-2%	-$689K	6.04%	4
2020 Q2	$37.8M	Buy	643,385 +36,596	+6%	+$2.19M	6.88%	4
2020 Q1	$33.8M	Buy	606,789 +4,186	+0.7%	+$256K	6.43%	4
2019 Q4	$38.7M	Buy	+602,603	New	+$34.5M	5.38%	8

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

J.L. Bainbridge & Co's BMY Position: Q1 2023 in Review

J.L. Bainbridge & Co sold out of Bristol-Myers Squibb (BMY) in Q1 2023, closing a stake of 303,693 shares — an estimated $21.9M sold.

J.L. Bainbridge & Co first reported a position in BMY in Q4 2019 and held it in 13 quarters. The position peaked at $42.7M in Q1 2022. 2,541 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

J.L. Bainbridge & Co reported no remaining Bristol-Myers Squibb position as of Q1 2023 after selling out during the quarter.
J.L. Bainbridge & Co sold 303,693 Bristol-Myers Squibb shares in Q1 2023, an estimated $21.9M.
J.L. Bainbridge & Co first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 13 quarters.
J.L. Bainbridge & Co's Bristol-Myers Squibb position peaked at $42.7M in Q1 2022.
2,541 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on J.L. Bainbridge & Co's 13F filing for Q1 2023, filed 4 May 2023.